Berenberg Bank Has Lowered Expectations for AstraZeneca (LON:AZN) Stock Price

AstraZeneca (LON:AZN – Get Free Report) had its target price dropped by Berenberg Bank from £160 to £150 in a research note issued on Tuesday, London Stock Exchange reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Berenberg Bank’s price target indicates a potential upside of 24.23% from the company’s current price.

Several other equities analysts have also recently weighed in on the company. Jefferies Financial Group restated a “buy” rating and issued a £175 price objective on shares of AstraZeneca in a report on Wednesday, September 9th. Citigroup upped their target price on AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a report on Tuesday, July 28th. Royal Bank Of Canada reissued an “outperform” rating and set a £145 price target on shares of AstraZeneca in a research report on Tuesday, September 8th. Finally, Deutsche Bank Aktiengesellschaft restated a “sell” rating and issued a £115 price target on shares of AstraZeneca in a research note on Wednesday, September 2nd. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, AstraZeneca presently has an average rating of “Moderate Buy” and an average price target of £149.71.

Get AstraZeneca alerts:

Read Our Latest Report on AstraZeneca

AstraZeneca Stock Down 0.7%

Shares of AZN stock opened at £120.74 on Tuesday. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 64.10. AstraZeneca has a 1 year low of £107.84 and a 1 year high of £157.32. The firm’s fifty day moving average price is £122.84 and its two-hundred day moving average price is £135.11. The firm has a market capitalization of £187.26 billion, a P/E ratio of 18.07, a PEG ratio of 0.86 and a beta of 0.20.

AstraZeneca Company Profile

(Get Free Report)

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Read More

• Five stocks we like better than AstraZeneca
• Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
• Institutional Money Is Pouring Into These 2 Altcoin ETFs
• The End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares
• 3 Dividend Kings to Buy While They’re Still Beaten Down

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.